325 related articles for article (PubMed ID: 36826026)
1. Immunotherapeutic Approaches in Ovarian Cancer.
Yoon H; Kim A; Jang H
Curr Issues Mol Biol; 2023 Feb; 45(2):1233-1249. PubMed ID: 36826026
[TBL] [Abstract][Full Text] [Related]
2. CAR-T therapy for ovarian cancer: Recent advances and future directions.
Xin Q; Chen Y; Sun X; Li R; Wu Y; Huang X
Biochem Pharmacol; 2024 Jun; 226():116349. PubMed ID: 38852648
[TBL] [Abstract][Full Text] [Related]
3. Next-generation sequencing-based genomic profiling analysis reveals novel mutations for clinical diagnosis in Chinese primary epithelial ovarian cancer patients.
Zhang L; Luo M; Yang H; Zhu S; Cheng X; Qing C
J Ovarian Res; 2019 Feb; 12(1):19. PubMed ID: 30786925
[TBL] [Abstract][Full Text] [Related]
4. Characterization of a Novel Third-Generation Anti-CD24-CAR against Ovarian Cancer.
Klapdor R; Wang S; Morgan M; Dörk T; Hacker U; Hillemanns P; Büning H; Schambach A
Int J Mol Sci; 2019 Feb; 20(3):. PubMed ID: 30717444
[TBL] [Abstract][Full Text] [Related]
5. The challenge of selecting tumor antigens for chimeric antigen receptor T-cell therapy in ovarian cancer.
Ding H; Zhang J; Zhang F; Xu Y; Yu Y; Liang W; Li Q
Med Oncol; 2022 Sep; 39(12):232. PubMed ID: 36175774
[TBL] [Abstract][Full Text] [Related]
6. Next Generation Sequencing and Molecular Biomarkers in Ovarian Cancer-An Opportunity for Targeted Therapy.
Harbin LM; Gallion HH; Allison DB; Kolesar JM
Diagnostics (Basel); 2022 Mar; 12(4):. PubMed ID: 35453890
[TBL] [Abstract][Full Text] [Related]
7. Molecular alterations and targeted therapy in pancreatic ductal adenocarcinoma.
Qian Y; Gong Y; Fan Z; Luo G; Huang Q; Deng S; Cheng H; Jin K; Ni Q; Yu X; Liu C
J Hematol Oncol; 2020 Oct; 13(1):130. PubMed ID: 33008426
[TBL] [Abstract][Full Text] [Related]
8. CAR-T cell therapy in ovarian cancer: from the bench to the bedside.
Zhu X; Cai H; Zhao L; Ning L; Lang J
Oncotarget; 2017 Sep; 8(38):64607-64621. PubMed ID: 28969098
[TBL] [Abstract][Full Text] [Related]
9. Identification and validation of pyroptosis-related gene landscape in prognosis and immunotherapy of ovarian cancer.
Gao L; Ying F; Cai J; Peng M; Xiao M; Sun S; Zeng Y; Xiong Z; Cai L; Gao R; Wang Z
J Ovarian Res; 2023 Jan; 16(1):27. PubMed ID: 36707884
[TBL] [Abstract][Full Text] [Related]
10. Limitations and potential of immunotherapy in ovarian cancer.
Kumar S; Acharya S; Karthikeyan M; Biswas P; Kumari S
Front Immunol; 2023; 14():1292166. PubMed ID: 38264664
[TBL] [Abstract][Full Text] [Related]
11. Insight updating of the molecular hallmarks in ovarian carcinoma.
Mota A; S Oltra S; Moreno-Bueno G
EJC Suppl; 2020 Aug; 15():16-26. PubMed ID: 33240439
[TBL] [Abstract][Full Text] [Related]
12. Nanomedicine Strategies for Heating "Cold" Ovarian Cancer (OC): Next Evolution in Immunotherapy of OC.
Yang Y; Zhao T; Chen Q; Li Y; Xiao Z; Xiang Y; Wang B; Qiu Y; Tu S; Jiang Y; Nan Y; Huang Q; Ai K
Adv Sci (Weinh); 2022 Oct; 9(28):e2202797. PubMed ID: 35869032
[TBL] [Abstract][Full Text] [Related]
13. Improved Killing of Ovarian Cancer Stem Cells by Combining a Novel Chimeric Antigen Receptor-Based Immunotherapy and Chemotherapy.
Klapdor R; Wang S; Hacker U; Büning H; Morgan M; Dörk T; Hillemanns P; Schambach A
Hum Gene Ther; 2017 Oct; 28(10):886-896. PubMed ID: 28836469
[TBL] [Abstract][Full Text] [Related]
14. Genetic and epigenetic strategies for advancing ovarian cancer immunotherapy.
Cho Y; Milane L; Amiji MM
Expert Opin Biol Ther; 2019 Jun; 19(6):547-560. PubMed ID: 30933545
[TBL] [Abstract][Full Text] [Related]
15. The Knowledge and Attitude of Patients Diagnosed with Epithelial Ovarian Cancer towards Genetic Testing.
Shin W; Jeong G; Son Y; Seo SS; Kang S; Park SY; Lim MC
Int J Environ Res Public Health; 2021 Feb; 18(5):. PubMed ID: 33652933
[TBL] [Abstract][Full Text] [Related]
16. Immunotherapy in ovarian cancer.
Krishnan V; Berek JS; Dorigo O
Curr Probl Cancer; 2017; 41(1):48-63. PubMed ID: 28169004
[TBL] [Abstract][Full Text] [Related]
17. Research progress of neoantigens in gynecologic cancers.
Song Y; Zhang Y
Int Immunopharmacol; 2022 Nov; 112():109236. PubMed ID: 36113318
[TBL] [Abstract][Full Text] [Related]
18. Immunotherapeutic approaches to ovarian cancer treatment.
Chester C; Dorigo O; Berek JS; Kohrt H
J Immunother Cancer; 2015; 3():7. PubMed ID: 25806106
[TBL] [Abstract][Full Text] [Related]
19. Comprehensive Analyses Identify APOBEC3A as a Genomic Instability-Associated Immune Prognostic Biomarker in Ovarian Cancer.
Xu F; Liu T; Zhou Z; Zou C; Xu S
Front Immunol; 2021; 12():749369. PubMed ID: 34745121
[TBL] [Abstract][Full Text] [Related]
20. The Role of Immunological Synapse in Predicting the Efficacy of Chimeric Antigen Receptor (CAR) Immunotherapy.
Liu D; Badeti S; Dotti G; Jiang JG; Wang H; Dermody J; Soteropoulos P; Streck D; Birge RB; Liu C
Cell Commun Signal; 2020 Aug; 18(1):134. PubMed ID: 32843053
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
